Showing results (31-40 of 61) with videos related to
Sort By:
Pageof 7
American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2018
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703)Eileen P Smith, Hongli Li, Jonathan W Friedberg, et al.Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm TrialGeorge E Georges, Dinesh Khanna, Mark H Wener, et al.Leukemia & Lymphoma|April 9, 2014
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivityColin Phipps, Ajay K Gopal, Barry E Storer, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2003
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseasesRichard A Nash, Roger Dansey, Jan Storek, et al.Journal of Hematology & Oncology|June 30, 2018
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantationRobert W Chen, Joycelynne M Palmer, Sarah Tomassetti, et al.The Journal of Clinical Investigation|December 13, 2022
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in miceSimone A Minnie, Olivia G Waltner, Kathleen S Ensbey, et al.Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.Pageof 7